Penn Medicine scientists including Basser Executive Director Susan Domchek, MD, and Basser Director of Genetics Katherine Nathanson, MD, recently published a paper on the PennChart Genomics Initiative.

We’re honored to award the 2020 Basser Global Prize to Bella Kaufman, MD, of Sheba Medical Center at Tel Hashomer in Israel. Dr. Kaufman has had a crucial role in the development of PARP inhibitors for the treatment of BRCA-related cancers. 

Early and repeated exposures to diagnostic imaging, such as X-rays and CT scans, may increase the risk of testicular cancer, according to a new study published in PLOS ONE and led by Katherine L. Nathanson, MD, Basser Director of Genetics.

Former NPR host Robert Siegel interviewed world cancer experts Dr. Susan Domchek, the Basser Center's Executive Director, and Dr. Mary-Claire King.

For Breast Cancer Awareness Month, Basser Center Executive Director Susan Domchek appeared as a guest on Pod is a Woman, Alejandra Campoverdi's podcast.

The Lancet published an article on the MEDIOLA trial, a study led by Basser Executive Director Susan Domchek, MD, which explored the use of PARP inhibitors and immunotherapy as treatment options for BRCA-related breast cancer.

The latest episode of the “CURE Talks Cancer” podcast features Basser genetic counselor Dana Farengo Clark discussing how genetic counseling is adjusting to the new normal and shifting into the virtual era of cancer care.

Basser Executive Director Susan Domchek, MD, is quoted in this discussion of the EMBRACA trial, which examined the PARP inhibitor talazoparib and its impact on BRCA-related breast cancer treatment.

Basser scientists were part of this Penn Medicine team effort studying PARP-1 expression and breast cancer.

Basser Executive Director Susan Domchek, MD, and Basser Director of Genetics Katherine L. Nathanson, MD, were involved in this study to examine the risk of various cancers associated with the PALB2 genetic mutation.